Skip to main content

Table 2 Cyst evolution in patients with significant renal cystic change (N = 11): PR - partial regression

From: Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution

Patient #

Duration of crizotinib (days)

No: of Cysts during study period

Mixed pattern of evolution of lesions

New cysts

Enlarged from baseline

Stable during study period

Regressed from baseline

Then regressed

Ongoing enlargement

CR

PR

1

280

2

Y

0

1

  

1

 

2

1344

1

N

0

 

1

   

3

678

2

Y

0

1

   

1; CR

4

126

5

Y

4

(+4)

1

   

5

686

4

Y

0

1

  

2

1; PR

6

150

3

Y

0

 

1

 

2

 

7

547

1

N

0

 

1

   

8

1109

4

Y

1

2 (+1)

  

1

 

9

160

2

Y

1

  

(1)

1

 

10

1477

1

N

0

  

1

  

11

1456

3

Y

2

1(+2)

    

Median age 48 years; 45% F; 64% Asian

Median 678

28

 

4/11 patients

13/28 cysts

4/28 cysts

2/28 cysts

7/28 cysts

2/28 cysts

  1. CR complete regression, (+) new lesion